Article
SGLT-2 Inhibitors’ Increased Risk of PAD-Related Surgical Events Compared to DPP-4 Inhibitors’ Risk When Used as Add-On Therapy in Diabetes
October 1, 2025
CLINICAL QUESTION: Do sodium-glucose cotransporter-2 (SGLT-2) inhibitors, as add-on therapy for diabetes, increase the risk of amputations, stent placement, or revascularization surgeries compared...
Article
Managing Inpatient Diabetes: Practical Pearls and Complex Scenarios
July 1, 2025
In this high-yield session, Lily Ackermann, MD, a clinical associate professor of medicine at Thomas Jefferson University Hospital in Philadelphia, addressed the complexities of inpatient diabetes...
Article
Effects of Semaglutide on CKD in Patients with Type 2 Diabetes: the FLOW Trial
April 1, 2025
Clinical question: Does treatment with semaglutide in patients with type 2 diabetes and chronic kidney disease (CKD) prevent the progression of CKD or death from kidney and cardiovascular...
Article
There is a Decreased Risk of Hospitalization from Heart Failure in Type II Diabetics Initiated on a SGLT2 Inhibitor When Compared to a GLP-1 Receptor Agonist
September 1, 2022
Dr. Huang Clinical question: Determine the cardiovascular risk outcome in type II diabetic patients initiated on an sodium-glucose cotransporter-2 (SGLT2) inhibitor versus a glucagon-like...
Article
Many hospitalized patients with type 2 diabetes and mild hyperglycemia on admission can be managed with sliding scale insulin alone
January 7, 2022
Dr. Knees Clinical question: In patients with mild hyperglycemia on admission, can sliding scale insulin (SSI) alone be used for blood glucose (BG) control? Background: Prior randomized...
![1]()
News
Care via video teleconferencing can be as effective as in-person for some conditions
December 6, 2021
Video teleconferencing works best for monitoring patients with chronic conditions, according to the author of a new paper.
![1]()
News
SGLT2 inhibitor use tied to fewer atrial arrhythmias
December 2, 2021
A prospective study of nearly 14,000 patients who received an implantable cardiac device suggests that SGLT2-inhibitor treatment cuts atrial arrhythmias.
![1]()
News
Empagliflozin a winner in challenging arena of stabilized acute HF
November 19, 2021
Early in-hospital initiation of SGLT2 inhibitors “should be considered the new standard of care” in most patients with heart failure regardless of their ejection fraction, says an expert observer.
![1]()
News
EMPEROR-Preserved findings confirmed in ‘true’ HFpEF patients
November 17, 2021
A landmark trial proved empagliflozin’s efficacy in HFpEF, but many patients had “moderately reduced” EFs. The findings hold up even without them.
News
Some diabetes drugs may lower risk of severe COVID-19 outcomes
October 19, 2021
Glucose-regulating medications may improve outcomes in COVID-19 patients with type 2 diabetes, a multinational retrospective cohort study suggests.
